US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs - Reuters

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQeWlmZ2xWUm9YUUxKcHN6bHpkRXBXRWFicjhQUDBEeHpiSUFtekxrZEo2SGM0MjFaR1QxeWpjODYxZ0N4Umh3OV9ydTVTMFVUV3FUX1RNeFIySHFzTV9XSUR2eS1OamY0SHFhMi1HekNKOU1Ba3BMM0h0SWNSdlA0QnFicHF3cVBOSFRQNmJDOUZNZzFrYV9hTGxrcS1kMk9rS2d6cU0wYklQd1dvbldPQ0RFUWN0aWFIeFl1MWxyOVJZWHRlTll1SFJzVmE?oc=5" target="_blank">US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

The FDA proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs from the list of substances that outsourcing facilities can use for compounding, potentially limiting large-scale production by these facilities.

The FDA proposed excluding semaglutide and tirzepatide, active ingredients in Novo Nordisk's and Eli Lilly's weight-loss drugs, from the list of substances that large compounding facilities can use, citing no clinical need for such compounding.

Shares in Novo Nordisk climbed more than 6% after the FDA proposed restricting the compounding of weight-loss medications, including semaglutide, tirzepatide, and liraglutide, stating there is no clinical need for outsourcing facilities to compound these drugs.

The FDA proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs from the list of drugs outsourcing facilities can use for compounding, stating there is no clinical need for such compounding.

The FDA proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing facilities and bolstering efforts against unauthorized versions that have been eating into sales of their blockbuster treatments.